| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hakan Silek, Ozgur Bilgin Topcuogl. Analysis of YouTube videos as a source of information for reliability and effectiveness of cannabidiol oil in treatment of epilepsy. Epilepsy & behavior : E&B. vol 138. 2022-12-15. PMID:36473301. |
analysis of youtube videos as a source of information for reliability and effectiveness of cannabidiol oil in treatment of epilepsy. |
2022-12-15 |
2023-08-14 |
Not clear |
| Hakan Silek, Ozgur Bilgin Topcuogl. Analysis of YouTube videos as a source of information for reliability and effectiveness of cannabidiol oil in treatment of epilepsy. Epilepsy & behavior : E&B. vol 138. 2022-12-15. PMID:36473301. |
cannabidiol (cbd) oil has been used for the treatment of refractory epilepsy for a long time. |
2022-12-15 |
2023-08-14 |
Not clear |
| Lindsay F Smegal, Pooja Vedmurthy, Matthew Ryan, Melissa Eagen, Nicole Whiston Andrejow, Kristie Sweeney, Teressa Garcia Reidy, SangEun Yeom, Doris D Lin, Stacy J Suskauer, Luther G Kalb, Jay A Salpekar, T Andrew Zabel, Anne M Com. Cannabidiol Treatment for Neurological, Cognitive, and Psychiatric Symptoms in Sturge-Weber Syndrome. Pediatric neurology. vol 139. 2022-12-12. PMID:36508880. |
a prior drug trial of cannabidiol for treatment-resistant epilepsy in patients with sturge-weber syndrome (sws), a rare neurovascular condition, implicated improvements in neurological, quality of life (qol), neuropsychologic, psychiatric, and motor outcomes. |
2022-12-12 |
2023-08-14 |
Not clear |
| Victoria Golub, Sreevidhya Ramakrishnan, Doodipala Samba Redd. Isobolographic analysis of adjunct Antiseizure activity of the FDA-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy. Experimental neurology. 2022-12-09. PMID:36493860. |
isobolographic analysis of adjunct antiseizure activity of the fda-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy. |
2022-12-09 |
2023-08-14 |
Not clear |
| Victoria Golub, Sreevidhya Ramakrishnan, Doodipala Samba Redd. Isobolographic analysis of adjunct Antiseizure activity of the FDA-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy. Experimental neurology. 2022-12-09. PMID:36493860. |
cannabidiol (cbd) has been shown to decrease seizures in pediatric epilepsies, such as dravet and lennox-gastaut syndromes; however, it has not been rigorously tested for adult seizures or in models of refractory focal epilepsy. |
2022-12-09 |
2023-08-14 |
Not clear |
| Aaron Del Pozo, Melissa Barker-Halisk. Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. Experimental neurology. vol 360. 2022-12-06. PMID:36471511. |
cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. |
2022-12-06 |
2023-08-14 |
Not clear |
| Aaron Del Pozo, Melissa Barker-Halisk. Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. Experimental neurology. vol 360. 2022-12-06. PMID:36471511. |
this commentary aims to review the historical relevance of cannabidiol's (cbd; epidiolex) approval for epilepsy in the context of other asms brought to market. |
2022-12-06 |
2023-08-14 |
Not clear |
| Aaron Del Pozo, Melissa Barker-Halisk. Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. Experimental neurology. vol 360. 2022-12-06. PMID:36471511. |
because of the clinical approval of cbd as a novel, cannabis plantderived asm for ds, cbd has revealed a new strategy in asm discovery to reignite 21st century therapeutic development for epilepsy. |
2022-12-06 |
2023-08-14 |
Not clear |
| John S Markowitz, Ludmila De Faria, Qingchen Zhang, Philip W Melchert, Reginald F Frye, Brandon O Klee, Yuli Qia. The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects. Medical cannabis and cannabinoids. vol 5. issue 1. 2022-12-05. PMID:36467779. |
cannabidiol (cbd) is a widely utilized nonpsychoactive cannabinoid available as an over-the-counter supplement, a component of medical cannabis, and a prescriptive treatment of childhood epilepsies. |
2022-12-05 |
2023-08-14 |
human |
| Antônio Silvinato, Idevaldo Floriano, Wanderley Marques Bernard. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Revista da Associacao Medica Brasileira (1992). vol 68. issue 10. 2022-11-23. PMID:36417631. |
use of cannabidiol in the treatment of epilepsy: lennox-gastaut syndrome, dravet syndrome, and tuberous sclerosis complex. |
2022-11-23 |
2023-08-14 |
Not clear |
| Vicente Villanueva, Adrián García-Ron, Patricia Smeyers, Eva Arias, Victor Soto, Juan José García-Peñas, Elena González-Alguacil, Débora Sayas, Pedro Serrano-Castro, Mercedes Garces, Kevin Hampel, Miguel Tomás, Julian Lara, María de Toledo, Ines Barceló, Angel Aledo-Serrano, Antonio Gil-Nagel, Lucas Iacampo, Mercè Falip, Rosa Ana Saiz-Diaz, Asier Gómez-Ibañez, David Sopelana, Alvaro Sanchez-Larsen, Francisco Javier López-Gonzále. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy. Epilepsy & behavior : E&B. vol 137. issue Pt A. 2022-11-03. PMID:36327646. |
outcomes from a spanish expanded access program on cannabidiol treatment in pediatric and adult patients with epilepsy. |
2022-11-03 |
2023-08-14 |
Not clear |
| Heidrun Potschka, Sofie F M Bhatti, Andrea Tipold, Stephanie McGrat. Cannabidiol in canine epilepsy. Veterinary journal (London, England : 1997). 2022-10-09. PMID:36209995. |
cannabidiol in canine epilepsy. |
2022-10-09 |
2023-08-14 |
human |
| Heidrun Potschka, Sofie F M Bhatti, Andrea Tipold, Stephanie McGrat. Cannabidiol in canine epilepsy. Veterinary journal (London, England : 1997). 2022-10-09. PMID:36209995. |
randomized controlled canine trials with large sample sizes are needed to determine the range of therapeutic plasma concentrations, develop evidence-based dosing regimens, determine the efficacy of cannabidiol in drug-refractory epilepsy, and explore potential associations between treatment effects and different etiologies, epilepsy types, and drug combinations. |
2022-10-09 |
2023-08-14 |
human |
| Ashna Talwar, Emily Estes, Rajender Aparasu, Doodipala Samba Redd. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Experimental neurology. 2022-10-07. PMID:36206805. |
clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: a systematic review and meta-analysis. |
2022-10-07 |
2023-08-14 |
Not clear |
| Doodipala Samba Redd. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies. Experimental neurology. 2022-10-07. PMID:36206806. |
therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies. |
2022-10-07 |
2023-08-14 |
Not clear |
| Willian Lazarini-Lopes, Carolina Campos-Rodriguez, Norberto Garcia-Cairasco, Prosper N'Gouemo, Patrick A Forcell. Cannabidiol attenuates generalized tonic-clonic and suppresses limbic seizures in the genetically epilepsy-prone rats (GEPR-3) strain. Pharmacological reports : PR. 2022-10-04. PMID:36195689. |
cannabidiol (cbd) has been of rapidly growing interest in the epilepsy research field due to its antiseizure properties in preclinical models and patients with pharmacoresistant epilepsy. |
2022-10-04 |
2023-08-14 |
rat |
| Ljubica Mihailova, Jana Tchekalarova, Dushko Shalabalija, Nikola Geskovski, Veronika Stoilkovska Gjorgievska, Gjoshe Stefkov, Paoleta Krasteva, Maja Simonoska Crcarevska, Marija Glavas Dodo. Lipid nano-carriers loaded with Cannabis sativa extract for epilepsy treatment - in vitro characterization and in vivo efficacy studies. Journal of pharmaceutical sciences. 2022-10-03. PMID:36189477. |
lipid nano-carriers loaded with cannabis sativa extract for epilepsy treatment - in vitro characterization and in vivo efficacy studies. |
2022-10-03 |
2023-08-14 |
Not clear |
| Ljubica Mihailova, Jana Tchekalarova, Dushko Shalabalija, Nikola Geskovski, Veronika Stoilkovska Gjorgievska, Gjoshe Stefkov, Paoleta Krasteva, Maja Simonoska Crcarevska, Marija Glavas Dodo. Lipid nano-carriers loaded with Cannabis sativa extract for epilepsy treatment - in vitro characterization and in vivo efficacy studies. Journal of pharmaceutical sciences. 2022-10-03. PMID:36189477. |
taking into consideration the latest reported beneficial anticolvusant effects of cannabidiol (cbd) and cannabiodiolic acid (cbda) for clinical applications and the advantages of lipid nano-systems as carriers for targeted brain delivery, the aim of this study was set in direction of in vitro physico-chemical and biopharmaceutical characterization and in vivo evaluation of nanoliposomes and nanostructured lipid carriers loaded with cannabis sativa extract intended for safe and efficient transport via blood-brain barrier and treatment of epilepsy. |
2022-10-03 |
2023-08-14 |
Not clear |
| Olabimpe Olafuyi, Karina Kapusta, Alexander Reed, Wojciech Kolodziejczyk, Julia Saloni, Glake A Hil. Investigation of cannabidiol's potential targets in limbic seizures. Journal of biomolecular structure & dynamics. 2022-09-21. PMID:36129109. |
in clinical and preclinical studies, various investigations have shown the advantage of specific plant-based cannabidiol (cbd) products in treating certain groups of people with limbic epilepsy who have failed to respond to conventional therapies. |
2022-09-21 |
2023-08-14 |
Not clear |
| Bakr Hameed, Md Rizwanullah, Showkat Rasool Mir, M Shaheer Akhtar, Saima Ami. Development of cannabidiol nanoemulsion for direct nose to brain delivery: Statistical optimization, in vitro and in vivo evaluation. Biomedical materials (Bristol, England). 2022-09-15. PMID:36108625. |
cannabidiol (cbd) is a prescribed drug for epilepsy but has low oral bioavailability and gastric instability. |
2022-09-15 |
2023-08-14 |
Not clear |